BrightSpring Health Services stock
BTSGNASDAQBrightSpring Health Services, Inc., HealthcareISIN US10950A1060
66Score 66 out of 100, Neutral
Price and trend
84 / 100
Price history
+114% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 30% above it.
Overheated: the price has risen very quickly lately (RSI 73).
The price is at its 52-week high. Largest decline in 3 years: 36% (January 2025 to April 2025).
Chart figures for advanced users
- SMA 50$61.51
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$55.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$31.36
- The lowest closing price of the last twelve months.
- Resistance$72.91
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BrightSpring Health Services, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $14.45B, is the largest of 25 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $16.01B (up 24%) and adjusted earnings per share of $1.92 (up 84.8%).
- MEQIRI Score 66 out of 100 (Neutral): rank 193 of 714 in Healthcare, median 53.
Show more
- The P/E is 41.5 (Medical (Healthcare Information Services) median 43, own median of recent years 39.8).
- Our model puts fair value at $92.96, with the price 22% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 23.9% a year through 2028 (estimates from 10 analysts).Growth 97
- Earnings turn into cashFree cash flow 119% of earnings over the last 12 months.Fundamentals 57
Weaknesses
- DilutionShare count up 18% since 2020.Capital allocation 43
- Interest barely coveredOperating profit covers interest only 1.9 times.Stability 48
- High debtDebt 1.09 times equity (latest quarter), Medical (Healthcare Information Services) median 0.34.Stability 48
Its standout strengths are growth and momentum, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
- high growth grade (crashed more often in the backtest)
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $66.40 and expensive above $154.94 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $110.64 (cash-flow model) and $75.29 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9%. At 10% the fair value would be $83.20, at 8% it would be $107.50.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 26.4% on the same quarter a year earlier. Up to 2024 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 24.3% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 12%, operating 2%, net not measured.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 30 Oct 2026EPS reported $0.54 (expected $0.47)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 7.7% since 15 Oct 2026.
- Earnings per share
- $1.92+5.7%
- Revenue
- $16.01B+4.4%
- Earnings per share
- $2.48+7.7%
- Revenue
- $18.5B+6.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −17.0%Full-year guidance updated after a quarter ahead of expectations: adjusted EBITDA is now expected at $820 million to $845 million and operating cash flow at about $600 million.
“Total adjusted EBITDA is now expected to be in the range of $820 million to $845 million for full year 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $877.75M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BrightSpring Health Services
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next smaller companies by market value
- Tempus AITEM $14.09B45
- Hinge HealthHNGE $9.82B70
- HealthEquityHQY $8.52B71
- M32413.T $7.7B73
- Alibaba Health Information Technology0241.HK $6.19B60
- DoximityDOCS $5.92B81
- Waystar HoldingWAY $5.55B60
- HeartflowHTFL $5.14B46
ETFs that hold BrightSpring Health Services
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.51% | 0.30% | €185.82M |
| Harbor Health Care UCITS ETF AccW311 | 0.48% | 0.89% | €11.61M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.40% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.39% | 0.30% | €2.17B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.33% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.11% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.10% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.10% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 22 Aug 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.